HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Taddeo, Frank J
Benediktsdottir, Kristrun R
MetadataShow full item record
CitationInt. J. Cancer 2007, 121(12):2682-7
AbstractThe distribution of human papillomavirus (HPV) varies between countries and continents leading to different effectiveness of upcoming prophylactic HPV vaccines. This study analyses the HPV distribution in CIN 2-3, recurrent CIN 2-3 and cervical cancer in Iceland. About 80% of incident cases with CIN 2-3 lesions in 1990 and 1999, 99% of cancer cases in 1990-1994 and 1999-2003, and cases with recurrent CIN 2-3 after conization in 1990 were tested with PCR analysis for the presence of 12 oncogenic HPV types. About 95% of the CIN 2-3 and 92% of the cancer cases tested positive for the included HPV types. HPV 16 was the most frequent type followed by HPV 33, 31, 52, 35, 18, 58, 56, 39, 45, 59 in CIN 2-3 and by HPV 18, 33 45, 31, 39, 52, 35, 51, 56 in cancer. HPV 16 and 18 were associated with a significantly increased cancer risk and HPV 52 and 31 with decreased cancer risk compared to the risk of CIN 3. The HPV distribution differed between histological cancer types, stages and age groups. The number of HPV types was not a significant predictor of cancer. Oncogenic HPV types were found in all persistent or recurrent CIN 2-3 disease after conization. Vaccination against HPV 16/18 is estimated to achieve a minimum 40% reduced rate of CIN 2-3 and a minimum 60% reduced cancer rate. This rate could, however, be increased to 95% and 92% respectively by including all the 12 HPV types tested for in this study.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?
- Authors: Nagai Y, Maehama T, Asato T, Kanazawa K
- Issue date: 2000 Nov
- [Study on the genotyping of human papillomavirus using a new DNA liquid chip in women of high-risk group of Shandong province].
- Authors: Liu M, Wang CX, Deng XM, Wang LS, Zhang J, Li W, Zheng GX, Wang JF
- Issue date: 2007 May
- [Human papillomavirus infection and cervical intraepithelial neoplasia].
- Authors: Sevcík L, Koliba P, Konderla M, Gráf P, Hlavacka J
- Issue date: 2003 Jul
- Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
- Authors: Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A
- Issue date: 2009 Dec 2
- Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis.
- Authors: Bodner K, Bodner-Adler B, Wierrani F, Kimberger O, Denk C, Grünberger W
- Issue date: 2002 Nov-Dec